![](https://static.wixstatic.com/media/8eb5c0_dd02624fc4ea43c780565b722d53f519~mv2.jpg/v1/fill/w_1280,h_720,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/8eb5c0_dd02624fc4ea43c780565b722d53f519~mv2.jpg)
![](https://static.wixstatic.com/media/8eb5c0_3cfa5228bb1b4b1595566da877f5af7a~mv2.png/v1/fill/w_980,h_695,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/8eb5c0_3cfa5228bb1b4b1595566da877f5af7a~mv2.png)
2025년 1월 20일
Global Recognition at the 2025 Functional Foods for Wellness Summit
ILDONG Bioscience, a subsidiary of the Ildong Pharmaceutical Group, announced on January 20th that its innovative postbiotic ingredient, BBR4401, has been recognized as the "Cardiovascular Health Ingredient of the Year" at the 2025 Functional Foods for Wellness Summit (FFWS).
The FFWS is an international event based in Asia that brings together leading companies, organizations, and experts in the functional food industry. The summit focuses on promoting the growth and innovation of the sector by addressing key topics such as emerging technologies, market trends, and academic research.
BBR4401, a heat-treated and dried culture derived from Bifidobacterium breve IDCC 4401, was developed exclusively by ILDONG Bioscience. It stands out as the first postbiotic in South Korea to receive individual recognition from the Ministry of Food and Drug Safety for its functionality in improving blood cholesterol levels. The ingredient works by binding with cholesterol and bile acids in the gut, promoting their excretion and stimulating the consumption of cholesterol during the enterohepatic circulation of bile acids.
Clinical studies conducted on Korean adults with LDL (low-density lipoprotein) cholesterol levels ranging from normal to borderline-high revealed the significant efficacy of BBR4401. Participants who consumed the ingredient experienced a noticeable reduction in LDL cholesterol levels and improved overall blood lipid profiles, underscoring its potential as a key solution for cardiovascular health.
ILDONG Bioscience has stated that BBR4401 is currently being used as a functional ingredient in health supplements designed to lower blood cholesterol. The company also plans to expand its applications by developing new products and increasing its focus on ODM (original development manufacturing) and raw material supply.
Established in 2016 as part of Ildong Holdings, ILDONG Bioscience specializes in functional food materials and products derived from probiotics and postbiotics. Leveraging Ildong Pharmaceutical's advanced technology and expertise in probiotics, the company engages in developing functional ingredients, providing contract development and manufacturing (CDMO) services, and supplying high-quality raw materials.
The recognition of BBR4401 at the FFWS highlights ILDONG Bioscience's commitment to advancing science-backed solutions in the functional food industry, solidifying its position as a leader in the development of innovative ingredients for cardiovascular health and beyond.